Trials / Completed
CompletedNCT00569140
A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration
A Phase 1, Single Ascending Dose Trial to Establish the Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Monotherapy and of E10030 Given in Combination With Lucentis®0.5 Mg/Eye in Subjects With Neovascular Age-Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Ophthotech Corporation · Industry
- Sex
- All
- Age
- 50 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of E10030 intravitreous injection when administered as monotherapy or in combination with Lucentis® 0.5 mg/eye in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E10030 | Intravitreal injection |
Timeline
- Start date
- 2007-12-01
- Completion
- 2008-12-01
- First posted
- 2007-12-06
- Last updated
- 2024-02-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00569140. Inclusion in this directory is not an endorsement.